- Investopedia•2 hours ago
Biotech stocks had a rough year in 2016, overall. The new year has brought new optimism among some investors, but there are still reasons to be cautious.
- Investopedia•21 hours ago
Biogen said its spinal muscular atrophy drug Spinraza fared well in a Phase 3 study.
- Zacks•23 hours ago
Biogen Inc. (BIIB) presented positive data from the phase III ENDEAR study evaluating Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||280.78 x 100|
|Ask||286.23 x 100|
|Day's Range||284.25 - 289.86|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.10|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|